Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
ATLANTA, Aug. 31, 2017 -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Rick Eiswirth, President and Chief Financial Officer, will present at the 19th Annual Rodman & Renshaw Global Investment Conference to be held September 10-12, 2017 at the Lotte New York Palace Hotel, New York, New York. Alimera Sciences’ presentation will take place Tuesday, September 12th, 2017 at 3:00pm Eastern Time.
A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Relations" section of the Company's website at www.alimerasciences.com. A replay of the conference presentation will also be available.
About Alimera Sciences, Inc.
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early-and late-stage diseases. For more information, please visit www.alimerasciences.com.
For press inquiries: Katie Brazel for Alimera Sciences 404-317-8361 [email protected] For investor inquiries: CG Capital for Alimera Sciences 877-889-1972 [email protected]
